evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/geneAliases/7,gene/geneAliases/8,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract
10440,GENE_SUMMARY,,"MED12 encodes a component of CDK8, a subcomplex involved in transcription initiation. MED12 plays a role in the genesis of benign tumors such as uterine leiomyoma and breast fibroadenoma and is mutated in a variety of estrogen-dependent human tumors.",,2017-04-26,,9968,MED12,mediator complex subunit 12,True,ENST00000374080,NM_005120.2,ARC240,TNRC11,TRAP230,OKS,MED12S,HOPA,CAGH45,FGS1,OHDOX,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10441,GENE_BACKGROUND,,"The MED12 gene encodes a component of the CDK8 subcomplex that is involved in transcription initiation. The MED12 protein is essential for activating CDK8 kinase. The CDK8 subcomplex which includes MED13, CDK8 kinase and cyclin C, modulates mediator-polymerase II interactions thereby regulating transcription initiation and reinitiation rates (RefSeq August 2009). The most commonly seen mutations in MED12 are in exon 2. Mutations in this domain have been described in uterine leiomyomas (PMID: 25108465, 24980722, 23443020, 23738515), breast fibroadenomas (PMID: 25038752), and Phyllodes tumors of the breast (PMID: 25593300). In benign breast tumors, MED12 hotspot mutations are thought to be early events that lead to deregulation of estrogen signaling (PMID: 25593300). MED12 is the most frequently mutated gene in uterine leiomyomas, suggesting it has a major role in the development of these lesions (PMID: 25108465). MED12 somatic exon 2 mutations have also been described in uterine leiomyosarcoma (uLMS) and colorectal cancer (CRC) (PMID: 23132392). The presence of the same MED12 mutations in uLMS as in uterine leiomyomas suggests that a subgroup of the malignant tumors may develop from a leiomyoma precursor. Leucine (L) to Phenylalanine (F) mutations at amino acid 1224 have been described in prostate cancer. These mutations are thought to play a role in tumorigenesis via perturbation of transcriptional programs linked to p53 and androgen signaling (PMID: 22610119).",,2017-04-26,,9968,MED12,mediator complex subunit 12,True,ENST00000374080,NM_005120.2,ARC240,TNRC11,TRAP230,OKS,MED12S,HOPA,CAGH45,FGS1,OHDOX,False,25038752,Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.,Nature genetics,2018-08-01T20:14:00,46,8,877-80,Lim WK et al,doi: 10.1038/ng.3037,,0001-08-01,,25108465,MED12 mutation frequency in unselected sporadic uterine leiomyomas.,Fertility and sterility,2018-10-01T20:14:00,102,4,1137-42,Heinonen HR et al,doi: 10.1016/j.fertnstert.2014.06.040,,0001-10-01,,24980722,Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.,Human mutation,2018-09-01T20:14:00,35,9,1136-41,Kämpjärvi K et al,doi: 10.1002/humu.22612,,0001-09-01,,23443020,MED12 exon 2 mutations in histopathological uterine leiomyoma variants.,European journal of human genetics : EJHG,2018-11-01T20:13:00,21,11,1300-3,Mäkinen N et al,doi: 10.1038/ejhg.2013.33,,0001-11-01,,22610119,"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.",Nature genetics,2018-05-20T20:12:00,44,6,685-9,Barbieri CE et al,doi: 10.1038/ng.2279,,0001-05-20,,25593300,Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.,Molecular cancer research : MCR,2018-04-01T20:15:00,13,4,613-9,Cani AK et al,doi: 10.1158/1541-7786.MCR-14-0578,,0001-04-01,,23132392,Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.,British journal of cancer,2018-11-06T20:12:00,107,10,1761-5,Kämpjärvi K et al,doi: 10.1038/bjc.2012.428,,0001-11-06,,23738515,Characterization of uterine leiomyomas by whole-genome sequencing.,The New England journal of medicine,2018-07-04T20:13:00,369,True,43-53,Mehine M et al,doi: 10.1056/NEJMoa1302736,,0001-07-04,
